Acquired Aplastic Anemia Market growth 2023 - Swot analysis, trends

Posted by vinit sawant on February 11th, 2021

The increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth during the period 2017-2023.

There are three major types of acquired aplastic anemia moderate aplastic anemia, severe aplastic anemia, very severe aplastic anemia. The patient with moderate aplastic anemia may have low blood cell count, but not as low as with severe aplastic anemia. The patient with severe aplastic anemia has platelet count, less than 20,000 per microliter. The patients with very severe aplastic anemia has a neutrophil count, less than 200 per microliter.

Patients with anemia may experience tiredness, increase need for sleep, weakness, lightheadedness, dizziness, irritation, headaches, may have pale skin color, difficulty breathing, and cardiac symptoms.

Segmentation

The global acquired aplastic anemia market is segmented on the basis of types, by diagnosis, by treatment, and by end user. On the basis of type, it is segmented into moderate aplastic anemia, severe aplastic anemia, and very severe aplastic anemia. On the basis of diagnosis, it is segmented into bone marrow biopsy, X-rays, computed tomography (CT) scans, and others. On the basis of treatment, it is segmented into bone marrow transplantation, immunosuppressive therapies, and others. On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.